AOBiome Announces Three Senior Management Appointments

Latest News

AOBiome Announces Three Senior Management Appointments

Cambridge, MA, May 18, 2015
AOBiome today announced three appointments to its senior management team to advance the company’s business to develop first-in-class skin health products based on Ammonia Oxidizing Bacteria (AOB). Joining the company are: Ramesh Ratan, Chief Financial Officer (CFO); Todd Krueger, Chief Business Officer (CBO); and Jim Hoffman, Head of Marketing.

“Ramesh, Todd, and Jim each bring decades of experience in leadership positions and outstanding track records in building and growing entrepreneurial biomedical and technology organizations,” said Spiros Jamas, ScD, CEO of AOBiome. “Our expanded management team positions us for our next stage of growth as we prepare to begin clinical trials with our first AOB-based therapeutic, for the treatment of acne, and accelerate the commercialization of our cosmetic business.”

Mr. Ratan has more than 35 years of experience in senior or executive vice president finance and operations positions at companies developing innovative biomedical technologies, including Xcellerex, Inc., Enanta Pharmaceuticals, Repligen Corp., and at technology companies such as American Superconductor Corporation, and Equinox Solutions, Inc. He continues to serve as CFO and Corporate Secretary at ABOVE Solutions Inc. He has been instrumental in raising over $150 million and negotiating numerous corporate alliances. He also held finance positions at Bristol-Myers Squibb.

Mr. Krueger has 20-years of experience in healthcare strategy, business development, operations and finance. He most recently led commercial efforts for the genomics platform at the Broad Institute. Previously, Mr. Krueger held senior positions at Claritas Genomics and Life Technologies. He has also been involved in the founding of several biotech startups, including Gynesonics, Nodality, Anestis Therapeutics and in 1999 he co-founded Fluidigm Corporation (NASDAQ: FLDM), serving as CFO and Vice President of Business Development. He serves on the board of directors of GALT, a microbiome tools startup. He started his career as a consultant for Bain and Company in Boston. Mr. Krueger graduated Highest Distinction from Northwestern University with a degree in Economics and earned his MBA from the Kellogg School of Management.

Mr. Hoffman joins AOBiome after a more than 35-year career as an entrepreneur leading companies to success in technology and marketing. He is a recognized expert industry source on issues affecting interactive marketing, web trends and standards. Mr. Hoffman has founded more than ten companies, including Section 101, which creates new revenue streams for major artists and brands by maximizing the value of their existing fans and by growing the customer base using a deep understanding of the target customer profile. He is also a founder of (sold in 2000), an email provider and web directory, and several spin outs: Bigfoot Interactive (sold in 2001), an e-mail direct marketing company and NeoPlanet (sold in 2005), a graphical web browser. He has also served President and CEO of Journal Graphics, Inc., the nation’s largest broadcast transcript company.

About AOBiome
AOBiome LLC is developing a transformative, new class of products based on Ammonia Oxidizing Bacteria (AOB) to improve skin health and prevent or treat skin and inflammatory diseases. The company’s probiotics are designed to provide cosmetic and therapeutic benefits by restoring the natural, protective balance afforded by beneficial skin microbes that have been lost due to modern living practices, including antibiotic use, soaps, and shampoos. AOB are ubiquitous bacteria that use oxidize ammonia and urea, two components in sweat, to produce nitrite, an anti-microbial compound, and nitric oxide, an important signaling molecule that helps the body manage skin and systemic functions. AOBiome is developing cosmetics and a pipeline of patented skin therapeutics to treat acne, rosacea and other inflammatory skin diseases.

The company was established in 2013 by its scientific founder, David Whitlock; biotech entrepreneur James Heywood, Co-founder of PatientsLikeMe and Founder of the ALS Therapy Development Institute; Lenny Barshack, a serial entrepreneur of technology companies; and Dr. Jamas. Learn more at

Recent News
4 January 2018, Cambridge, MA
AOBiome Therapeutics Appoints Todd Krueger as Chief Executive Officer

19 October 2017, Cambridge, MA
AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris

3 October 2017, Cambridge, MA
AOBiome Commences Patient Enrollment in Phase 1b/2a Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Seasonal Allergic Rhinitis

20 September 2017, Cambridge, MA
AOBiome Expands Intellectual Property Estate, Announces Issuance of U.S. Patent for Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne

13 April 2017, Cambridge, MA
AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure

4 March 2017, Cambridge, MA
American Academy of Dermatology selects AOBiome study for presentation at Annual Meeting

5 January 2017, Cambridge, MA
AOBiome Partners with iCarbonX and Secures $30 Million Investment for Drug Development

16 December 2016, Cambridge, MA
AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension

20 September 2016, Cambridge, MA
AOBiome Announces First-of-its Kind Trial of Live Topical Bacterial Treatment for Acne

31 December 2015, Cambridge, MA
AOBiome Wins Dermatology Entrepreneurship Shark Tank Contest

7 July 2015, Cambridge, MA
Mother Dirt Rethinks what it means to be Clean and Healthy with First-Ever Line of Biome-Friendly Products for the Skin

29 June 2015, Cambridge, MA
AOBiome co-founder, Jamie Heywood named by Scientific American, as one of The Worldview 100, The visionaries who continue to reshape biotechnology-and the world

22 June 2015, Cambridge, MA
AOBiome Announces Start of First Clinical Trial with Ammonia Oxidizing Bacteria-Based Therapeutic for Treatment of Acne

18 May 2015, Cambridge, MA
AOBiome Announces Three Senior Management Appointments

2 Oct 2014, Washington, DC
American Society for Microbiology Reports Sweat-Eating Bacteria May Improve Skin Health

20 Jun 2014, Cleveland, OH
Accelerated Healing of Diabetic Ulcer Data Presented

16 Jun 2014, Cambridge, MA
AOBiome in the News

19 May 2014, Cambridge, MA
AOBiome announces appointment of scientific advisory board

30 Jun 2013, Cambridge, MA
Nitrocell becomes AOBiome LLC